Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 studyHoward I. Scher, Charles L. Sawyers, Evan Y. Yu et al.|The Lancet|2010Cited by 1.1k
Detection of T790M, the Acquired Resistance <i>EGFR</i> Mutation, by Tumor Biopsy versus Noninvasive Blood-Based AnalysesTilak Sundaresan, Daniel A. Haber, Lecia V. Sequist et al.|Clinical Cancer Research|2015Cited by 345
Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate CancerDana E. Rathkopf, Howard I. Scher, Michael J. Morris et al.|Journal of Clinical Oncology|2013Cited by 264
Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate CancerDavid Lorente, Johann S. de Bono, David Olmos et al.|European Urology|2016Cited by 154